UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

Journal der Deutschen Dermatologischen Gesellschaft, 2022-10, Vol.20 (10), p.1386-1402

2022

Volltextzugriff (PDF)

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

Journal der Deutschen Dermatologischen Gesellschaft, 2022-10, Vol.20 (10), p.1386-1402

2022

Volltextzugriff (PDF)

S2k‐Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion

Journal der Deutschen Dermatologischen Gesellschaft, 2017-08, Vol.15 (8), p.860-873

2017

Volltextzugriff (PDF)

S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion

Journal der Deutschen Dermatologischen Gesellschaft, 2017-08, Vol.15 (8), p.860-873

2017

Volltextzugriff (PDF)

311nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Photodermatology, photoimmunology & photomedicine, 2011-08, Vol.27 (4), p.186-189

2011

Volltextzugriff (PDF)

Retrospektives Langzeit-Follow-up nach erfolgreicher Bade-PUVA-Therapie bei chronischen palmoplantaren Dermatosen

Journal der Deutschen Dermatologischen Gesellschaft, 2012-11, Vol.10 (11), p.814-819

2012

Volltextzugriff (PDF)

668 - Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

51219 Lebrikizumab Monotherapy Maintained Improvement of Itch and Sleep-Loss Due to Itch After Two Years in Patients with Moderate-to-Severe Atopic Dermatitis

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB58-AB58

2024

Volltextzugriff (PDF)

52100 Improvement of itch and sleep disturbance symptoms in patients with moderate-to-severe atopic dermatitis treated with lebrikizumab is maintained over 52 weeks as measured weekly with POEM

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB236-AB236

2024

Volltextzugriff (PDF)

667 - Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii6-ii7

2024

Volltextzugriff (PDF)

41916 Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB61-AB61

2023

Volltextzugriff (PDF)

Stellenwert der Phototherapie in der Behandlung des chronischen Pruritus

Hautarzt, 2018-08, Vol.69 (8), p.631-640

Legat, Franz J.

2018

Volltextzugriff (PDF)

733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

33307 Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB185-AB185

2022

Volltextzugriff (PDF)

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_3)

2023

Volltextzugriff (PDF)

Successful thalidomide therapy for actinic prurigo in a European woman

Journal der Deutschen Dermatologischen Gesellschaft, 2006-11, Vol.4 (11), p.961-964

2006

Volltextzugriff (PDF)

Effects of FR173657, a non‐peptide B2 antagonist, on kinin‐induced hypotension, visceral and peripheral oedema formation and bronchoconstriction

British journal of pharmacology, 1997-03, Vol.120 (5), p.933-939

1997

Volltextzugriff (PDF)

Effects of the non‐peptide B2 antagonist FR173657 on kinin‐induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release

British journal of pharmacology, 1997-06, Vol.121 (3), p.469-476

1997

Volltextzugriff (PDF)

The cutaneous neurosensory system in skin disease

Advances in dermatology, 2002, Vol.18, p.91

2002

Volltextzugriff (PDF)

Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling

European journal of pharmaceutics and biopharmaceutics, 2012, Vol.81 (3), p.655-661

2012

Volltextzugriff (PDF)

Psoralen plus UVA vs. UVB-311nm for the treatment of lichen planus

Photodermatology, photoimmunology & photomedicine, 2007-02, Vol.23 (1), p.15-19

2007

Volltextzugriff (PDF)

Erfolgreiche Thalidomidtherapie einer kaukasischen Patientin mit hereditärer aktinischer Prurigo

Journal der Deutschen Dermatologischen Gesellschaft, 2006-11, Vol.4 (11), p.no-no

2006

Volltextzugriff (PDF)

The inflammatory response by a house dust mite extract in non-sensitized rats is caused by 5-hydroxytryptamine from mast cells

Journal of dermatological science, 1998-03, Vol.16, p.S180-S180

1998

Volltextzugriff (PDF)

Arzneimittelallergie

Pharmakotherapie, p.479-493

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

ThemaMedicine, General & Internal

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(25)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

S2k‐Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion

S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion

311nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Retrospektives Langzeit-Follow-up nach erfolgreicher Bade-PUVA-Therapie bei chronischen palmoplantaren Dermatosen

668 - Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)

51219 Lebrikizumab Monotherapy Maintained Improvement of Itch and Sleep-Loss Due to Itch After Two Years in Patients with Moderate-to-Severe Atopic Dermatitis

52100 Improvement of itch and sleep disturbance symptoms in patients with moderate-to-severe atopic dermatitis treated with lebrikizumab is maintained over 52 weeks as measured weekly with POEM

667 - Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis

497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis

41916 Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

Stellenwert der Phototherapie in der Behandlung des chronischen Pruritus

733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data

33307 Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

Successful thalidomide therapy for actinic prurigo in a European woman

Effects of FR173657, a non‐peptide B2 antagonist, on kinin‐induced hypotension, visceral and peripheral oedema formation and bronchoconstriction

Effects of the non‐peptide B2 antagonist FR173657 on kinin‐induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release

The cutaneous neurosensory system in skin disease

Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling

Psoralen plus UVA vs. UVB-311nm for the treatment of lichen planus

Erfolgreiche Thalidomidtherapie einer kaukasischen Patientin mit hereditärer aktinischer Prurigo

The inflammatory response by a house dust mite extract in non-sensitized rats is caused by 5-hydroxytryptamine from mast cells

Arzneimittelallergie

Aktive Filter

Suchergebnisse filtern